Heart failure is a common, costly, and potentially fatal condition which in 2020 affected about 64 million people globally and about 15 million people in EU. The patients suffer from end-stage heart failure and are in desperate need of a heart transplant. However, transplants are extremely limited and current solutions (artificial hearts and other mechanical circulatory support systems) do not offer a sustainable long-term solution due to unsolved medical consequences such as thromboembolism and bleeding.

Scandinavian Real Heart AB (Realheart) offers a total artificial heart (TAH), the first-of-its-kind wearable permanent solution that delivers physiological flow and pressure, based on the natural human heart’s pumping principle. The unique pulsating blood flow is expected to create many advantages over the currently available products and those in development. Realheart’s goal is to develop a wearable permanent TAH to save the lives of thousands of heart failure patients.